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ABSTRACT Incontrasttousuallaboratoryconditions,mostbacteriainthehumanbodygrowinbioﬁlms.Encasedinastructured
matrix, many pathogens display heightened resistance to antibiotics. Pseudomonas aeruginosa lung infections in cystic ﬁbrosis
patientsrepresentaprimeexampleoftheclinicalchallengesthatantibioticresistanceinbioﬁlmscanrepresent.IntheMarch6,
2012issueofmBio,ColinHillandhiscolleaguesreportonexperimentsthataddtotheevidencethat Pseudomonasphagesarea
potentialtreatmentoptionfortheseinfections.
W
ithanincidenceof1outof3,500livebirths,cysticﬁbrosis(CF)
is the most common life-threatening autosomal recessive ge-
netic disease in Caucasian children. The causative mutations are lo-
cated within a single gene, the CF transmembrane regulator. Half of
the affected patients show a deletion of a speciﬁc phenylalanine resi-
due(F508),butthegenotype-phenotyperelationshipiscomplex.It
hasbeenproposedthatthestrikinglyhighprevalenceofthisdeleteri-
ous mutation could be due to a higher resistance to toxin-induced
diarrhea or tuberculosis among heterozygotes.
CF affects the gut and the pancreas (exocrine pancreas insufﬁ-
ciency leads to malabsorption and failure to thrive), but for most
CF patients, life expectancy is determined by the development of
lung disease. The failure to clear thick and abundant mucous se-
cretions from the lung leads to chronic coughing at a young age,
followedbyfrequentlunginfections,includingrepetitiveepisodes
of pneumonia. Chest percussion to remove the secretions and
antibiotics constitute a mainstay of treatment. However, for most
CF patients, recurring lung infections ﬁnally lead to end-stage
lungdisease,whichcanbetreatedonlywithlungtransplantation.
The median survival age for CF patients is currently 32 and
29 years for men and women, respectively.
ThemicrobiologyofCFiscomplex.Staphylococcusaureuscol-
onizes the lung in 30% of CF patients early in life. Small, slow-
growing colony variants displaying antibiotic resistance, including
methicillin-resistant S. aureus (MRSA) strains, are characteristically
found. In early adolescence, the lungs typically become chronically
infectedwithPseudomonasaeruginosa;upto80%ofadultCFpatients
are colonized with this pathogen. Nonmotile, anaerobic, mucoid
variants of P. aeruginosa grow in a bioﬁlm within the lungs, a struc-
ture that confers resistance to antimicrobials.
Since today’s CF patients reach adulthood, still other faculta-
tive pathogens have a chance to enter the lung. Bacteria of the
Burkholderia cepacia complex, for instance, are now recovered
from 10% of the lungs in adult CF patients. Burkholderia infec-
tions can transform a mild pulmonary case into a rapidly deteri-
orating lung infection associated with bacteremia and death
within6months.Evenamongpatientswithalessdramaticcourse,
some surgeons consider Burkholderia infections to be a contrain-
dication for lung transplantation. In hospital settings,
Burkholderia-infected patients should be segregated from other
CF patients to prevent nosocomial spread of the pathogen.
Since lung infections are the life-limiting factor for CF patients
and since the major CF pathogens are increasingly difﬁcult to treat
with antibiotics, alternatives or adjuncts to antibiotics are urgently
needed.ThemBioarticlebyColinHillandhiscolleagues(1)provides
anencouragingoutlookinthisregard.Theauthorsexploredthepos-
sibility of treating P. aeruginosa infections with bacteriophages, an
attractive potential therapeutic option for several reasons.
First, S. aureus and P. aeruginosa are classical targets of the
Soviet phage therapy approach. The Russian company Microgen
currently sells phage preparations against both pathogens, either
singly or in combination, for treatment of pyogenic infections.
Frequentlyusedfortreatingpulmonaryinfections,theseproducts
are registered medicines in Russia. Second, it is relatively easy to
isolate “virulent” (as opposed to “temperate”) phages against the
three major pathogens of CF patients. Large collections of phages
of S. aureus, P. aeruginosa, and B. cepacia exist, many of which are
fullysequenced.Thisisnotatrivialstatement,sincephagesarenot
isolated easily against any bacterial species.
Third, the aforementioned phages have a broad host range.
Unlike antibiotics, most phages are strain speciﬁc, making them
targetedtothepathogenofinterestandpreventingcollateraldam-
age to commensal bacteria. However, this speciﬁcity can be a
problem for treatment, and often a cocktail of different phages is
needed to achieve a reasonable coverage of a given pathogenic
species. Fortunately, phages against CF pathogens have a good, if
notanexcellent,pathogencoverage.PhageK,forinstance,infects
nearly half of S. aureus isolates from large collections, and phage
Stau2 infects 80% (2).
Fourth, the efﬁcacy of phage therapy approaches has been
demonstratedinanimalinfectionmodelswithCFpathogens.For
example, B. cenocepacia bacterial density in the lung was reduced
afterintraperitonealbutnotintranasalphageapplicationtomice.
The lytic effect was speciﬁc to the replication-competent phages,
since no lytic effect was seen with UV-inactivated phages or a
phage that had no in vitro lytic activity against the infecting Burk-
holderia strain. Phages showed ampliﬁcation in the lung and re-
duced pathogen-induced inﬂammation signs. In treated mice,
phages were colocalized with degraded bacteria in perivascular
lung areas and alveolar septa (3).
The recent article by Alemayehu et al. (1) provides suggestive ev-
idence that bacteriophages might also be of use against P. aeruginosa
infection.Theyshowedthatsuitablephagescanbeisolatedfromsew-
age, a common starting material for phage isolation. By sequencing
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therapeuticphages,anessentialconditionforlaterphageapplication
in human subjects. They then reported that the phages infect Pseu-
domonasgrowinginabioﬁlm.Finally,theauthorsdemonstratedthe
efﬁcacy of intranasally applied phages in a P. aeruginosa lung infec-
tion model using state-of-the-art imaging techniques (although it
should be noted that mice do not get chronically infected with
P. aeruginosa, so bioﬁlms are thus not formed in this transient infec-
tion model). Mice treated with intranasal phage at a phage-to-
bacterium ratio of 1:1, but not with lower ratios, survived a lethal
P. aeruginosa infection.
The data reported by Alemayehu et al. (1) conﬁrm previous
observations from other groups and therefore represent impor-
tant steps toward developing effective CF phage therapy.
Fittingly, work on phage therapy for P. aeruginosa infection con-
tinuesatthePasteurInstituteinParis,wherephagesandphagether-
apywereﬁrstdescribedbyFelixd’Herellenearly100yearsago.Using
bioluminescent P. aeruginosa, Debarbieux et al. (4) demonstrated a
rapid killing of bacteria in phage-treated animals and a reduction in
inﬂammatory markers. The researchers selected phages which grew
well on clinical P. aeruginosa isolates from CF patients and showed
thattheyachieveddose-dependentprotectioninamouselunginfec-
tion model (5). Phages showed in vivo replication, decreased the al-
veolar pathogen load, and prevented histopathologic lesions. Phage
treatmentcouldbedelayedforafewhourswiththesameresults,and
administering the phages a day before pathogen challenge also pre-
vented the infection. When phages were administered to uninfected
mice,theypersistedfor5daysinthelung,suggestingthepotentialfor
preventive phage use.
Similarly, the bioﬁlm activity of Pseudomonas phages reported in
theAlemayehuetal.articleconﬁrmsearlierwork.Britishresearchers
found that phages had bacteriocidal effects on Pseudomonas in bio-
ﬁlms (6). When using excess phages, a 100-fold bacterial titer de-
creasewasobserved.Pseudomonasphagescouldalsodiffusethrough
8% alginate gels, which mimic the conditions in Pseudomonas bio-
ﬁlms. Digestion fragments from the alginate were released from
phage-treated polymers. Phage researchers from the Republic of
Georgiaandstructuralbiologistssubsequentlyshowedthatthedepo-
lymerizing enzyme is part of the phage particles (7, 8).
Pretreatment with phages may also eventually be feasible. Re-
searchers at the Centers for Disease Control and Prevention
(CDC) in Atlanta, GA, demonstrated that pretreating catheters
with a cocktail of Pseudomonas phages prevented bioﬁlm forma-
tion. Intact but not heat-killed phages achieved a 1,000-fold titer
reduction of the bacteria in the bioﬁlm grown on a catheter in the
presenceofhumanserum(9).Thelatterobservationisimportant,
sinceinthetransitionfrombenchtobed,thedevilisinthedetails.
TheleadauthorsoftheAlemayehuarticleobservedthisforthem-
selves in earlier work, in which they explored the potential of
S. aureus phages for treating bovine mastitis. In that study, they
found that milk contained an inhibitory activity that inactivated
the broad-host-range S. aureus phage K (10), a fact that explains
the observations from Canadian researchers who failed to detect
an in vivo inhibitory effect of phages on bovine mastitis.
DespitethesetbackswithS.aureusphageuseinfarmanimals,the
prospects for applying Pseudomonas phages in humans are encour-
aging.ThreeclinicaltrialsthataddressPseudomonasinfectionsinve-
nouslegulcers(Intralytix),burnpatients(Belgianmilitary)(11),and
the outer ear canal (causing diseases ranging from mild swimmer’s
ear to necrotizing otitis externa in diabetics and AIDS) (Biocontrol,
United Kingdom) have been registered. So far, no adverse effects of
phagetreatmenthavebeenobserved.InacontrolledphaseIIclinical
trial, 24 otitis externa patients received either a single small dose of
Pseudomonas phage cocktail or a placebo. The researchers found ev-
idenceforinvivophagereplication,adecreaseinPseudomonascounts
in some patients, and symptom amelioration in most of the treated
patients (12). One might criticize the study for its small size and for
thefactthatonlypatientswithPseudomonasearinfectionsusceptible
to the applied phage were enrolled, but the study set a standard for a
detailedcombinedclinical,microbiological,andstatisticalevaluation
of phage therapy approaches.
The three senior authors of the mBio article (1) are members of
PhageWorks, a phage solution company recently founded in Cork,
Ireland, by scientists working in two important research organiza-
tionsoftheIrishgovernment:theTeagascFoodResearchCentreand
the Alimentary Pharmabiotic Centre. The current study relies on
yearsofresearchinthedairyﬁeld,butonehopesthattheknowledge
acquiredinthefoodsectoronpracticalaspectsofphageresearchcan
eventually serve the biomedical research community and the devel-
opment of therapeutic applications for phages as well. This reminds
me of the words of Louis Pasteur, who wrote, “There are similarities
betweenthediseasesofanimalsandhumansandthediseasesofbeer
andwine.”FortheCorkresearchers,hemighthavespokenof“cheese
and yogurt.” Looking beyond the fences of one’s “own professional
specialization” can lead to important cross-fertilization.
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